PubMed=9354451
Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M., Gabrielli B.G., Parsons P.G., Hayward N.K.
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=9466661; DOI=10.1002/(SICI)1097-0215(19980209)75:4<590::AID-IJC16>3.0.CO;2-D
White C.A., Thomson S.A., Cooper L.T., van Endert P.M., Tampe R., Coupar B., Qiu L., Parsons P.G., Moss D.J., Khanna R.
Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.
Int. J. Cancer 75:590-595(1998)

PubMed=10338330; DOI=10.1097/00008390-199902000-00003
Rizos H., Darmanian A.P., Indsto J.O., Shannon J.A., Kefford R.F., Mann G.J.
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells.
Melanoma Res. 9:10-19(1999)

PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Johansson P., Pavey S., Hayward N.K.
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007)